R emarkablea dvancesi no ncologyt herapy have created significantimprovements in survival ando ften decreased chemotherapy-induced toxicity.A ssociatedw itht hese advances isacost.Managed care must always weighadvancesand theirassociatedcostst odetermine if thecombination represents value. In addition,m anaged care administrators must develop treatment decision processes andc overagep olicies. Doings oi s rarelyeasy.
Cancerr esearchers usuallyl ooka t2e ndpoints when they investigatenew therapies: time-to-progressionand survival.They aren ot usuallyconcernedwithcost.W orkp ublished in 2004 in the NewEnglandJournal of Medicine,however,did look at theescalatingc ost of cancerc area nd itsr elationshipt os urvival. 1 With no therapyp rior to the1 960s,patientswho hadm etastaticcolorectal cancer( CRC) couldb ee xpected to survivea pproximately 8months. Adding single therapywithfluorouracilinthe mid-1960s increasedm edians urvivalt oa bout 1y ear. When combination therapy( fluorouracilp lusl eucovorin plus oxaliplatin,F OLFOX) wasa pprovedbythe U.S. Food andDrugAdministration( FDA), survival lengthened to 21 months.T he newerb iologica gents (FOLFOXp lusb evacizumab)i ncreased survival further, so that patients with metastaticC RC routinely survivef or 2y ears. 2 The doubling of immediate survival came about with a3 40-fold, or greaterthan$21,000,increaseindrugcost forthe initial8weeks. Regardless,t his mayb eag ood return on investment, because nowsurvivalismeasuredinyears as opposedtomonths.
Despitet he magnitudeo ft he increase in sheerc ost,t he actualb udgeti mpacti nm anaged care has continuedt ob e relatively small.The priceoftreatment is only 1factorthatman-aged care must weigh. That pricec an be exceptionallyh ighf or individuals, butt he population size is remarkably low, creating ap er-member-per-month( PMPM)i mpactt hati ss ometimes almost negligible-unliket reatmentst hath ave moderate costs buta re usedu biquitously,s ucha sstatins, antidepressants,a nd proton pump inhibitors.T reatment duration hast endedt ob e reasonably short. Usingt hese agents also offsetso ther costs, by eliminatingthe need forsurgery or decreasing hospitalizationor length of stay,a nd theiri ncremental benefitsa re elusive. Thus, cancertherapies have escapedmanaged care's aggressivenotice.
Much of managedc are'sd ifficulty with antineoplastics and canceristhatmanaged care administrators tend to lump allcosts together formanyd isease states andc anceri np articularw hen, in reality,c anceri sag roup of diseases.M anaged care is adept at tracking silo costsrelated to pharmacy,laboratory, andm edicalb udgets andc osts. An additional con founder is thechangeinthe wayth eCenters forMedicare&MedicaidServices( CMS) planst oreimburse for Medicare,w itha ne ye toward reducing itsc osts. Traditionally, Medicare reimbursement wasb ased on actualw holesalep rice (AWP)d iscounting, nott he oncologist's purchasing cost of thec hemotherapeutica gent. This allowedo ncologists to use reimbursement fori nfusions to supportt heir medical practices. In all fairness,t he marginso nt hese products couldb es ignificantb ecause thef ee schedule wasc onstructed irrationally. Oncologistsmight be underpaidf or clinicalw ork, buto verpaid fordrugadministration, leadingtoakindo fbalance.Therefore, achangeinone reimbursement type tendstoleadtochanges in theother.
Medicare'sp roposedp lan is to use average sales price( ASP) plus 6% to reimbursef or drugsu sedi nt he office setting. However, that in andofitselfleads to significantproblems. Thus, CMS initiated demonstrationp rojectst om itigatet he extreme decrease in aggregateo ncology reimbursement. Some people knowledgeablea bout CMSd emonstration pro jectsi ndicatet hat they were designed as temporarybridges to alleviate oncologists' cash flow problems pursuantt ot he impact of theASP plus6 % plan-ad ecreasei np hysician reimbursementf rom$ 130p er patientper dayin2005to$23 pervisit in 2006 forreportingdata as part of thed emonstration project. 3 Others indicate that the demonstrationp rojectsare proofthatMedicareknows thatthey can't change thes ystem significantly, andt heya re usingt hese project to ensure thatcliniciansare paid adequately. 4 Thereality is probably somewhere betweenthese 2extremes, butthe change is importantbecause,inoncology, medications arecrucial.
Antineoplastica gentsa ccounted for1 6% of thet otal dollars spento nm edications in theU nitedS tatesi n2 004.F or 2007, theN ationalCancerI nstitute projectsthatantineoplastica gents will consumea lmost aq uartero ft he overall drug spend. 5 The Pharmaceutical Researchand Manufacturerso fAmerica reports that,in2005, therewere3 99 chemotherapeutic agents in development. Thus,c hemotherapeutica gentsa ccountedf or half of all drugsi nd evelopment, and3 5% of thea gentsb eing tested were formulated as oral agents. 6 This is attractingatremendous amount of attention, especiallya mong investors. Additionally, themedia is making thecost of theseagentsintoleading stories, ando ne storyp remisei st hatw heni nsurance companies have difficultymanagingordenyaccess to an agent, 7 themanufacturer can setvirtuallyany price.
This meanst hatm anaged care pharmacy departmentsm ust become involvedi ns omed ecisions regardingo ncologyc are. This is an ew phenomenon.P harmacyh as notb eenc oncerned with traditionalc hemotherapyb ecause it wasp rimarily given parenterally andc overed by Medicare Part Ba so pposed to Medicare Part D. Instead, chemotherapy hastraditionally been a concernf or physicians' officesand hospitals. Thea dvento fo ral agents is changing ther eimbursement structure, andm anaged care pharmacy will need to integraten ew agents with theo lder medications andcreatecomprehensivecoverage. Thedifficultyis thatthisisaveryemotional subject because of thelife-threatening nature of CRC, andthe advocatesfor increasedavailability of new treatmentsr egardless of cost or evidence form as trongl obby. Advocateswill scrutinize effortstomanagecancerdrugs,and the amount of feedback andc omment tendst ob ed isproportionate compared with thenumberofpatientsactuallyaffected.
Pharmacy andt herapeutics( P&T) committeesw ill alsof ace challenges as they trytodevelop rational formularies. Fewerdata thanu suala re available fors omeo ft hese agents because they have becomea vailable throught he FDA'sF astT rack,P riority Review,orAccelerated Approval processes.Manyagents' approvalsmay be basedonsurrogate endpointsratherthanclinical outcomes. 8 With combinationt herapy increasingly more prevalent forC RC,n ew agents replaceo lder drugs; they augmentt hem, andprovide no cost offset whatsoever.Whenalternativescan be offered, patients atisfactionr emains high.W itho nlyal imited number of products FDA-approvedtotreat CRC, it is impossible to select preferreda gents. Similaro rg eneric products aren ot available as substitutes. 8 
■■ Cost andSurvival
Returningtothe openingexample of a2-foldincreaseinmedian survival form etastaticC RC compare dw itha3 40-foldi ncrease in cost,t hisc an translatei ntoc onsiderableb udgetary impact. And, in othertypes of cancer, similarsituationshave developed. Imatinib, forexample,increased survival in chronicmyelogenous leukemiasignificantly. The3-yearsurvivalrateis95% compared with 68%to7 0% previously. 9 Itsmonthly cost,h owever, ranges from $3,082 to $6,164,depending on thedoseemployed. Other examples arem ores triking. Sorafenib, recentlya pproved for advanced or metastaticr enal cell carcinoma, increaseds urvival from ameanof84daysusing placeboinpatientswho hadfailed previous treatmentt o1 67 days.( No agentwas considered standard of care in this cancerprior to sorafenib'sapproval, whichis whythe FDAallowed aplacebo-controlledtrial.) Onecan look at this as doubling survival or thatthe survival is still only 83 days. Thec ost of therapyf or an additional 83 days of lifeis$ 28,000. Extrapolatingthe cost to months andyears leadstoanenormous cost estimate. 10 Finally, erlotinibwas approvedf or non-small-cell lung cancer, offering amedian increase in survival of approximately 2months-from 4.7monthswithplacebo andtraditional therapyto6.7 months with erlotiniba nd traditionalt herapy. 10 Thec ost of that extra 2m onthso fs urvivale quates to slightly more than $14,000.Our systemswill have to absorb thesenew costs.
■■ Creating Context
Managedcareisbeginningt oestablish abenchmark describing thequality-of-life-per-year cost in termsofcost-effectiveness.For example, an ew product, panitumumab, wasa pprovedf or the treatmento fm etastaticC RC in patients whoh ave progressed on standard chemotherapy.T hisd rug, like many others, was fast-tracked basedonthe resultsofatrial of only 463patients.
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Survival wass imilar in both thet reatment andc ontrol groups, butthe mean time to progressionwas 36 days longer forpatients treatedwithp anitumumab. 12 Itsa ctualp ricing is approximately $2,000 perw eek. Pharmacy departmentso rresponsemanagers must nota pproachthe cost of therapiesf or cancerinavacuum, ands houldd evelop ac ontext within whichc ost is onee lement of al argerp icture.T hese costsa re high relative to some issues; $14,000 to extend life for2m onthsi sn ot excessivec ompared wiht he costso fah ospitals tay, am ajors urgery,h omec are, or things of that nature.A ppropriate benchmarks should be other typesofcaregiven to thesepatients, whichispartofthe overall cost of cancer. Managed care hasroomfor improvement in evaluatingt he cost of care in general, andc anceri np articular. Our approacht oe nd-of-life issues is awkward; we prefer to discuss quality-of-lifeissues.
Onek ey wayt oi mprove quality of life fort erminalc ancer patients is good pain management. 13 Benchmarks forp ain management should encouragec ancer patients to manage pain effectivelya th ome. Better antineoplasticsa re also needed;t hey should be less toxicthanpreviouslyusedagentsand offerlonger survival.Quality of life, however, will only be sustainedifpatients can access otherservicesd uringthattimespan. Otherwise, the months of additional survival areo fp oorq uality,r epresenting abad outcome forall involved. 14 Oncology disease management programs must reacho ut to patients andnot necessarilydeal with theoncology issuesdirectly, buta ddress thet angentiali ssuest hati mpactc are, especially depressiona nd pain management.P &T committeesm ustn ot contemplatethe issuesand make decisionsinavacuum; many of thesedecisions aresocietal issuesconcernedwithdetermining the valueofnew therapiesmonetarilyand otherwise. In this respect, American societydiffersfromother cultures.For example, in the United Kingdom, combinationt herapy is notf irst-linef or CRC; fluorouracili s. If progressiono ccurs, combinationt herapy is likelythe next step.Americanshave notcollectivelymadeasingle decision about howC RC will be managed; individual care providers make thed ecisions.S erious national debate is needed on issues like this,and Medicare'sefforts areafirst step in that direction.Amoreintricate frameworkormatrixwould help us evaluate thesekinds of productsinterms of thecostssocietyiswilling to bear.D evelopinga nd usingab etterf rameworkw ould remove insurancecompanies,employers,patients, pharmacies,and individual oncologists from thed ebateo fw hatp rioritiess houldb e andwhere ourefforts arebestplaced. Unless Americansunite and deal with thesei ssues, individualsw ill continue to have to sort throughatremendousnumberofproblemswithlittleguidance.
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